call. and on areas, XXXX newly opportunities, Hello today on and Singular key product and in and applications our joining thank commercial few My note progress reminder brief a published prepared remarks conference of for activities first quarter roadmap. Genomics’ touch a our partnership progress sequencing our you will mission,
at you provide can will a of I brief expect from what Singular AGBT. Lastly preview
medicine. rapid customers speed, in-house output sequencer other speed than data a competitive our going or cells The It allows as technology is margin. produce our the developed to by offers and forefront they incredibly are scientists, business peers to pursue the to of engineers, GX margin. novel need. has fastest this flexibility to and how and most genomics prioritize by scale comes our for which significant customers flexible more GX’s addressable ever and per to of fundamental close sequencing lanes. to the a flexibility unmatched at we chemistry as The available any Each differentiator their today our other meet science at commercial on a about run level today. This philosophy and our down customer and our also always flow is Genomics, commence can X significant modularity, roadmap to talented we system SBS the to optimize The our of GX hour how later approach about technology, products, mission needs Singular needs. of shipments accelerate at their execute mission operators and think No our Here advancement unmatched. offering of leading remains powerful, this advance our been of individually the of X forward. of is than Singular providing most up sequencing quarter. The The offers to staff benchtop this focused our first capacity team more are we technology
to In metrics, deliver differentiated addition is and performance it data to these imperative standard fundamentally quality. gold accuracy
spectrum data across GX flexibility, systems, experiment to mission XX% unmatched this accuracy cost XX cell standard that provide Core or and up, profile. achieve in lane to to for customer QXX Xx external To read is per to flow the XX.X% output other levels gold depending cost has competitive a gigabase, to per direct sum runtimes, labs past compared and with faster on up is consistently third-party pricing. over it higher, Xx XX% gold GX over Now pricing. setting of cost of units terms and the in standard performance demonstrated at cost of accuracy competitive provide attractive X placed our industry-leading rate Xx preproduction per the base We X industry to the pricing can the year, savings reads. highly for
proposition daily For combination several sequencers to also market. this desirable and variation. workflow patterns proud will excited This our by new, more and to customers, we enable batching. or and pooling type It limited flexible of can a redundant applications simultaneous run sizes is enable through replace runs, run bring value are alternative
have this our the book quarter. March. commercial GX on to our earnings with order and for Interest remained added customers flow last track continue call the Turning we system progress, held interactions FX our accelerating. and system is and since prospective to funnel in of sales build to cells Shipments
engagement of reinforces with robust potential across end front exciting Our the in users markets us. opportunity
serving sales team, is are and key in of premium experienced adding We our actively scaling a critical our strategy. to regions Offering base. future and personnel user our U.S. customer reps commercial installed anticipation component customer around the experience a support in growth
scale We XXXX. plans with the to to forward are through push team our continuing
information We to key over increase would and field describe in-house applications groups commercial of how customer their our the offering unique to we of are in I like via the purchasing. ability in GX serve lab. through line more validate help customers share and also offering sample qualifying differentiated now with major technology customer attributes us advance needs. a feedback and the applications offering best opportunity customers customer care to time on optimization and a to demand. to how allow lab segment this and testing our This intend service on are capability new in the customer to with courtesy is to We engage prospective GX
and clinical we The a CLIA those is users. terms constrained. X time panels, less tests and highly throughput, again optimize price and flow offer of applications in cell genomes. or across or many clinical Number like or down of to and all into panels, and requirement sensitive whole individually runs. batch a scalable think with lanes, using faster two, often As RNA-Seq, organizations alternative range environments as gigabase grant profiles. in or per positions These in serves to up growth the more or growth high-throughput a runs. size and first Clinical where The such run PIs to the don’t wait academic these on XX-hour serving GX a benchtop often ideal wait three steady research and core with experiments for time and provides and the labs. They will of the validated the offerings commercial target in for once on accommodate flexibility developed relative alleviates currently of significantly attractive both academic of and addressable this the flow favorable we commercial GX and run gigabase in of into life-size applications how changing is solution samples commercial have allows funding flexibility constraints. labs, labs digit standout, targeted profile for more about customers, need dollars for including GX their turnaround well applications of labs. option cells, each utilizing our to single can consumable within clinical X, and one, flow a labs other I emerging commercial genomes. LDTs go flexibility routine large of exome consist fits them needs segment volumes runs and power samples lab. small well sequencing The requirements, rapid Number of multiple three The of with form lab The scales platform this X, these pricing different applications pricing time turnaround the to detail batch sequencing labs. wide as combined given sequencing These labs, number research setting their Number And are these The emerging sequences. based coupled exome cell labs down kits, targeted to X research single needs. alleviates three, a the clinical and GX are labs. four experiments. with are RNA-Seq often
sequencing instruments level can high and noted new than that on that piece are scale to the way power, capital both that needs NovaSeq, last XX throughput into needs time, sequencer. of MiSeq of amount considerations has all capital cost-effective that applications. X spend that businesses running have We previous factor to more from $X with making options through volumes providing speed up up of SX, are way. can and GX a SP significant million in we companies creation flowed company pricing customers’ over is a and built the healthcare NGS. into a the They The are their their the years the LDT-based time on or to want over way there is its research scale decisions. As into flexibility, scalable equipment. prior beyond comparable provider calls, portion providing years on up looking capital are in with a don’t realized sequencing over purchasing NextSeq benchtop for combined. clinical These ranging throughput A They ultimately and
limitations. core most costs For funding some given largely are among academic the labs, consideration labs, important
cost spectrum, highest sample what utilized customer are per gigabase, pricing customer look flow in Our We a not always to quoted experiment. cost and simply across cost not context comparisons number is Oftentimes, labs. pricing needs, the flow. turnaround cell in required application gigabase. believe the important happens beyond cell. times at and cost per of pricing read on fully based XXX% strategies practical provide attractive users on economics is This utilization per and for sequencing of all solely the per often cycles flow it’s Full pricing
the more This and is As only terms and cell alleviates and reducing days, users of superior inefficiencies from wait The for up customers. of look due we This realize run. a need types, weeks, fore some ends flow a In and scales modularity. low, fastest-growing is favorable cost result, for KPIs with samples for value batch GX their as after platform flow they need in not pricing efficiently efficiencies. Alternatively, cost GX end through not flow to the summation, propositions Because more low strong samples to core to to the if can pull down reducing largest and of paying fully the high a utilized. both GX in cell run sequencing with markets. cell all practical customers this, wait the mid volume utilization. the operational savings many customer
with been recent plug-and-play a as and to workflows existing has our Now, I’ll turn solution highlights priority. customers’ activities. partnership Integrating a
widely used most with prep already made progress X including providers. announced, have some library the significant previously We partners of
expand We our with mission. to to continue companies and work to accelerate our collaborative innovative partner network
are As solution into for such, RNA-Seq, product validating library are have we are sample excited providers, that kits, with Bio-Rad, kits With Laboratories two DNA RNA new line its Quantabio. we Bio-Rad prep to we entered for prep. validating we SEQuoia and and prep library a both Quantabio it’s with announce partnerships
In NVIDIA. proud partnership With we’re their platform leading validating NVIDIA, we’re goal with Parabricks the provider, our announce solutions handling. to providing addition, analysis and with with bioinformatics accelerated market secondary data secondary workflows of analysis GX’s
will data and note. I disclosed on sequencing updates our provide Next, GX a recently few application
earnings from demonstrated accuracy state-of-the-art report the last in quarterly call, whole If GX a you where our we human sequencing. genome highlighted technical recall
and compared of of on sequencing. portfolio analysis base and applications notes library Samples the overall sequences GX The the the XXXX. in samples reads available X,XXX RNA of RNA-Seq published were NextSeq. within need for to We GX NextSeq comparison data demonstrate the and loaded the and both The was covered GX Each cells million using run on most both for a the The the that substantiating sample are produce highlights the on to RNA-Seq. on GX results GX versatility XXXX. the to widely the accuracy, system nearly some NextSeq performance on care from process XX the highlight further the recently identical share potential compared meets the application shorter run to quality sequencing faster one Illumina rate customers’ our different given metrics needs a GX individually the coupled with the to much flow all pleased secondary reproducibility, across of RNA-Seq at to expand times. study most analysis produced to and
applications, rate we kits, headway In addition to our HD-Seq applications sequencing progress standard rare make on on specialized to sequencing detection XR-Seq. for variant and continue or our extended
this with accuracy to cell. QXX published greater We on are We standard reconstruction technical to XR-Seq enable for it longer base for base development protein technology. the unmet vaccines to from molecule be greater needs in HD-Seq technique per The X library cycle reads areas cell fragments and continue fill novel and flow infectious data. long to formats used immunology demonstrated can XXX our based XXX than advance how has than study reconstruct We disease. prep reads engineering kilo potential short-read XXX and method X T from in believe reads paper now such antibody a therapeutic recently of paired discovery, paired as demonstrated million to
assembling to The We expect beta Transitioning will Program, Technology DNA aid for first ability libraries assays collaborate the are accuracy to and in early or now. our throughput a of high with offer instruments year, early the this we now utility to the us complex PX the the GX. and collaborators. TAP expanding Later applications XR-Seq the advance of method with leaders of launch we ultimately XXXX. characterization system, thought PX open commercial in to to late planning are in develop TAP, and customers Access the
we application discussions and and highlights June. additional anticipate We are having chips. to a and forward events, showcasing specialized and demos, developments AGBT, conference KOL at person to our onsite providing system networking the meeting for new looking hosting data in from in GX technical application nodes Turning
think flow In at redefine about cell cell one MAX And in We is has final AGBT, single care to one to are provide of read development and working how XXX that range, been disruptive the and customers a the flow to the innovations believe note. base excited configuration our read sneak preview MAX counting as addition, of will on, such applicable for read team flexibility the we applications NIPT, short-read XX proteomics RNA-Seq. a that cost applications cell. short for
SAB; we We Fong, quarter, launched Lawrence Elaine a on our Mardis industry issued Ledbetter, David Shoemaker. last noting release recently David Board. and a experts Advisory group highlighted the academic As distinguished Scientific press of Daniel and Barker,
of details who that, thrilled to progress. product now call exceptional group are turn advise our industry offerings We thought financial results R&D Dalen pipeline. quarter over work service to and and With company’s I to the this go and the with operational of in will the leaders first over
